RFK Jr. grilled on Medicare: What is Medicare Part A, Medicare Part B and Medicaid? What are they?
Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation ...
RFK Jr. second hearing takeaways: GOP criticism, more Medicare fumbles, and DEI
RFK Jr.'s second Senate confirmation hearing focused on vaccines, Medicare, diversity, and science. Key Republicans were reticent to show support.
CMS to seek Medicare negotiations on Ozempic price
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Does Medicare cover ketamine infusions for mental health conditions?
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
JD Supra14h
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
Latest Medicare price drug negotiations includes Ozempic, Wegovy
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3%, to $457.25, ...